Advance
Beyond's analysis on Advance
- — Abogen’s mRNA T‑cell engager deal with Novartis expands immunotherapy pipeline and validates its RNA platform
- — Abogen licenses its mRNA-encoded T-cell engager to Novartis, expanding the latter's immuno-oncology pipeline
Recent news mentioning Advance
- — Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs
- — Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs
- — SAS, NC State Launch AI Think & Do Tank to Advance Health Research
- — Ochsner opens The Debra H. and Robert J. Patrick Neuroscience Institute, transforming access to advanced neurological care across the Gulf South
- — CaseBioscience® Joins Team Awarded Up to $7.3 Million by ARPA-H to Advance Ambient Preservation of Cell Therapies
- — CaseBioscience® Joins Team Awarded Up to $7.3 Million by ARPA-H to Advance Ambient Preservation of Cell Therapies
- — AsiaStrategy Signs Memorandum of Understanding with Plume Network to Advance Real-World Asset Tokenisation Across Asia
- — Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
- — Uriage Presents New Scientific Advances in Triple Barrier Science at EADV Congress 2026 in Vienna
- — Koning Health Announces Agreement with HealthTrust Performance Group, Expanding Access to Advanced Breast CT Technology
- — KSAT Advances Global Lunar Communications Network
- — NORD Awards Seed Grants to Advance Breakthroughs in Rare Disease Research